Corroborating a recent report [15], our study highlights that UBE2J2 and UBE2K are two important functional partners of MARCH5 in regulating apoptosis in AML cells and can serve as additional targets for enhancing venetoclax efficacy. Here, UBE2J2 is linked to acute myeloid leukemia.